The α1‐Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Evidence supports a role for the noradrenergic system in alcohol drinking in animals and humans. Our previous studies demonstrated the efficacy of prazosin, an α1‐adrenergic antagonist, in decreasing alcohol drinking in rat models of alcohol dependence. Prazosin has also been shown to decrease alcohol drinking in treatment‐seeking alcohol‐dependent men. Clinically, the use of prazosin is limited by the requirement for multiple daily administrations, whereas doxazosin, a structurally similar α1‐adrenergic antagonist, requires only once‐daily dosing. In this study, we tested the hypothesis that doxazosin, like prazosin, would decrease alcohol drinking in rats selectively bred for alcohol preference (P line). Methods: Adult male P rats were given 2 h/d scheduled access to a 2‐bottle choice (15% v/v alcohol vs. water) session 5 d/wk (M–F), with food and water available ad libitum 24 h/d. Rats were injected with doxazosin (0 to 10 mg/kg, IP) 40 minutes prior to initiation of the alcohol access session in 3 trials (of 3, 5, and 5 consecutive days) each separated by 5 to 8 weeks. The third trial included 1 day without alcohol access (for locomotor testing), and 1 day of a single hour of alcohol access (for plasma alcohol determination). Results: Doxazosin significantly reduced alcohol intake in all 3 trials. The 5 mg/kg dose consistently reduced alcohol intake, increased water drinking, did not affect locomotor activity, and resulted in lower plasma alcohol concentrations, suggesting that the doxazosin‐induced reduction in alcohol drinking was not dependent on a motor impairment or an alteration in alcohol clearance. Conclusions: Doxazosin decreases voluntary alcohol consumption by male alcohol‐preferring (P) rats, supporting a role for the noradrenergic system in alcohol drinking in P rats and suggesting that doxazosin could potentially be an effective once‐daily pharmacotherapeutic agent for the treatment of alcohol use disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 2×
“5% in the United States, and is associated with significant personal and societal costs (Hasin et al., 2007; Samokhvalov et al., 2010; Thavorncharoensap et al., 2009).”
BackgroundInfluential
Cited by
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Doxazosin decreased voluntary alcohol intake in alcohol-preferring rats in a dose-dependent manner, and this effect was likely not due to general motor impairment [204].”
BackgroundNoradrenergic targets for the treatment of alcohol use disorder
Haass-Koffler, C. L., Swift, R. M., & Leggio, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4843-6 · Cited by 117
Vanderkam, P., Solinas, M., Ingrand, I., Doux, N., Ebrahimighavam, S., Jaafari, N., & Lafay‐Chebassier, C. (2021) · Addiction · doi:10.1111/add.15265 · Cited by 25
Metadata
- Authors
- O'Neil, M. L., Beckwith, L. E., Kincaid, C. L., & Rasmussen, D. D.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2012-07-03
- Volume
- 37
- Issue
- 2
- Pages
- 202-212
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W4233807684
- Cited by
- 41
- References
- 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The α1‐Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats. https://app.cochat.ai/papers/10.1111/j.1530-0277.2012.01884.x
- The paper
- O'Neil, M. L., Beckwith, L. E., Kincaid, C. L., & Rasmussen, D. D. (2013). The α1‐Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2012.01884.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.